Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin versus acarbose for endothelial function in type 2 diabetes
NL-OMON32871Phase 3Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2010
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vildagliptin and acarbose in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Forearm vasodilatory response to acetylcholine and sodium nitroprusside. Started Jan 2010; status: active, not recruiting.
02
Drugs
vildagliptinacarbose
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON32871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32871.